Quantcast

Latest Embryonic stem cell Stories

2014-08-21 08:28:11

- Welcomes New Shareholders Who Received Series A Shares from Geron Corporation - MENLO PARK, Calif., Aug. 21, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno and Natale ("Nat") Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three...

2014-08-14 12:27:58

Computer algorithm also provides 'quality assurance' for lab-created cells BOSTON, Aug. 14, 2014 /PRNewswire-USNewswire/ -- In a boon to stem cell research and regenerative medicine, scientists at Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a "roadmap" for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable...

2014-08-12 08:30:36

SYDNEY, Aug. 12, 2014 /PRNewswire/ -- The Australian biotechnology company, Novogen Limited (ASX: NRT; NASDAQ: NVGN), today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD). http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO FSHD is one of the most common forms of muscular dystrophy and genetic hereditary...

2014-08-08 11:20:47

Cell Transplantation Center of Excellence for Aging and Brain Repair Induced immunorejection may eliminate tumors post-cell transplantation Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation. In an...

2014-07-24 16:26:46

- Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - MENLO PARK, Calif., July 24, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias' business strategy and product development pipeline. To...

Discovery Of Gene May Make It Easier To Develop Life-saving Stem Cells
2014-07-21 03:53:38

Michigan State University Not unlike looking for the proverbial needle in a haystack, a team of Michigan State University researchers have found a gene that could be key to the development of stem cells – cells that can potentially save millions of lives by morphing into practically any cell in the body. The gene, known as ASF1A, was not discovered by the team. However, it is at least one of the genes responsible for the mechanism of cellular reprogramming, a phenomenon that can turn...

2014-07-17 23:05:39

According to a new report from BCC Research, the global market for induced pluripotent stem cells (iPSCs) is expected to grow to $2.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 19.7%. The Asia-Pacific market, the fastest performing regional segment, is projected to move at a significant CAGR of 22%. (PRWEB) July 17, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS, the global market for...

2014-07-17 08:30:21

SAN DIEGO, July 17, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, today announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes. The trial would evaluate the safety and efficacy of ViaCyte's VC-01(TM) product candidate, a stem...

2014-07-16 12:27:46

EWING, N.J., July 16, 2014 /PRNewswire/ -- Essential Pharmaceuticals LLC, Ewing NJ announces the release of Cell-Ess® serum replacement for cell culture. Cell-Ess is a replacement for the Fetal Bovine Serum (FBS) that is commonly used in cell culture. The product is chemically defined, animal component free and delivers critical components that are needed for cell growth. http://photos.prnewswire.com/prnvar/20140715/127335 Cell-Ess enables researchers to eliminate FBS use in...

2014-07-15 12:28:25

Accepted to stem cell treatment, but insurance won't cover it POLLOCK PINES, Calif., July 15, 2014 /PRNewswire/ -- Marc Serchia, 56, is waiting on a miracle, and if the doctors are correct he doesn't have much more time. At the age of 39, Marc suffered a massive heart attack, faced a 5-hour surgery to repair blocked arteries, and died on the surgical table six separate times. Unbelievably, he survived, but with a severely damaged heart. Doctors wouldn't put him near the top of the...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'